Assessing Boston Scientific’s Valuation As Lower Guidance Weighs On Sentiment After Strong Q1 Results

Endpoints NewsBristol Myers’ pivotal year; Should AI be swinging bigger?; and more

Eli LillyWhy Eli Lilly (LLY) Is Up 9.0% After Q1 Beat And Foundayo GLP‑1 Launch - And What's Next - simplywall.st

WuXi BiologicsWuXi Biologics Advances Global Sustainability Strategy With 2025 ESG Report - BioPharma APAC

Novo NordiskFDA Proposal Could Support Novo Nordisk GLP‑1 Exclusivity And Valuation - simplywall.st

AmgenBiopharma bites: Novo rebrands Rybelsus as the Ozempic pill, and Amgen trims its pipeline - FirstWord Pharma

Samsung BiologicsUnionized workers of Samsung Biologics continue strike for 2nd day - lokmattimes.com

Samsung BiologicsSamsung Biologics union continues strike regarding wages, other issues - Korea JoongAng Daily

Samsung BiologicsUnionized workers of Samsung Biologics continue strike for 2nd day - The Korea Herald

Boston ScientificAssessing Boston Scientific’s Valuation As Lower Guidance Weighs On Sentiment After Strong Q1 Results - simplywall.st

Lab-DirectCardiovascular Pacing and ICD Leads Price in Northern America - Market Insights - IndexBox

Merck KGaAMerck KGaA Backs Hybrid Cancer Drugs And Greener Lab Consumables - simplywall.st

BioPharma DiveArvinas’ ‘Protac’ breast cancer drug cleared by FDA